Adel Nada, GentiBio CEO
At an 'inflection point': GentiBio reels in $157M ahead of what CEO Adel Nada sees as a Treg boom
GentiBio CEO Adel Nada says regulatory T cells (or Tregs) are now where CAR-Ts were at the beginning of the last decade — at an inflection …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
